JP2019535232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535232A5 JP2019535232A5 JP2019502698A JP2019502698A JP2019535232A5 JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5 JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding portion
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022035222A JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614162.4 | 2016-08-18 | ||
| GBGB1614162.4A GB201614162D0 (en) | 2016-08-18 | 2016-08-18 | Antibodies, uses thereof and conjugates thereof |
| PCT/GB2017/052448 WO2018033749A1 (en) | 2016-08-18 | 2017-08-18 | Anti-psma antibodies, uses thereof and conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035222A Division JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535232A JP2019535232A (ja) | 2019-12-12 |
| JP2019535232A5 true JP2019535232A5 (enExample) | 2020-09-17 |
| JP7039554B2 JP7039554B2 (ja) | 2022-03-22 |
Family
ID=57045541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502698A Active JP7039554B2 (ja) | 2016-08-18 | 2017-08-18 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
| JP2022035222A Active JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035222A Active JP7486538B2 (ja) | 2016-08-18 | 2022-03-08 | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11059903B2 (enExample) |
| EP (2) | EP3500595B1 (enExample) |
| JP (2) | JP7039554B2 (enExample) |
| CN (1) | CN110049999B (enExample) |
| ES (1) | ES2983492T3 (enExample) |
| GB (1) | GB201614162D0 (enExample) |
| WO (1) | WO2018033749A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| MX2020009272A (es) | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| SI3773910T1 (sl) * | 2018-03-29 | 2024-10-30 | Ambrx, Inc. | Konjugati zdravila in humaniziranega protitelesa proti za prostato specifičnemu membranskemu antigenu (PSMA) |
| EP3994177A4 (en) * | 2019-07-02 | 2023-09-20 | Telix International Pty Ltd | Antibodies for binding psma with reduced affinity for the neonatal fc receptor |
| US11766453B2 (en) | 2019-09-11 | 2023-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs) |
| US20220411530A1 (en) * | 2019-11-22 | 2022-12-29 | Nantong Yichen Biopharma. Co. Ltd. | PSMA Antibody and Use Thereof |
| CN110922486B (zh) * | 2020-02-18 | 2020-05-22 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| EP4673474A2 (en) | 2023-02-28 | 2026-01-07 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| ES2281101T3 (es) | 1996-07-24 | 2007-09-16 | Koninklijke Philips Electronics N.V. | Mejoras en y en relacion a discos legibles opticamente y aparato de grabacion de discos. |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| ES2606537T3 (es) | 2001-10-23 | 2017-03-24 | Psma Development Company L.L.C. | Anticuerpos contra PSMA |
| US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| HRP20120709T1 (hr) | 2005-02-18 | 2012-10-31 | Medarex, Inc. | Humano monoklonsko protutijelo za prostata-specifiäśni membranski antigen (psma) |
| WO2006089231A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US9364557B2 (en) * | 2007-08-01 | 2016-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fold-back diabody diphtheria toxin immunotoxin and methods of use |
| BRPI0818288A2 (pt) | 2007-10-09 | 2015-04-14 | Polytherics Ltd | Proteínas conjugadas e peptídeos. |
| CN101891818B (zh) * | 2009-01-16 | 2012-07-25 | 中国人民解放军第四军医大学 | 抗人前列腺特异性膜抗原胞外区单链抗体及其应用 |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| CA2876365A1 (en) * | 2012-06-19 | 2013-12-27 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| IN2015DN02349A (enExample) | 2012-10-24 | 2015-08-28 | Polytherics Ltd | |
| BR112015023679A2 (pt) * | 2013-03-15 | 2017-10-24 | Memorial Sloan Kettering Cancer Center | composições e métodos para imunoterapia |
| JP6908964B2 (ja) | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| WO2015057250A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| JP6517240B2 (ja) | 2014-05-22 | 2019-05-22 | シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． | 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ |
| KR20230158134A (ko) | 2014-10-14 | 2023-11-17 | 폴리테릭스 리미티드 | Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법 |
| JP6612860B2 (ja) * | 2014-10-24 | 2019-11-27 | ポリセリックス・リミテッド | コンジュゲート及びコンジュゲート試薬 |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
-
2016
- 2016-08-18 GB GBGB1614162.4A patent/GB201614162D0/en not_active Ceased
-
2017
- 2017-08-18 JP JP2019502698A patent/JP7039554B2/ja active Active
- 2017-08-18 WO PCT/GB2017/052448 patent/WO2018033749A1/en not_active Ceased
- 2017-08-18 EP EP17757849.9A patent/EP3500595B1/en active Active
- 2017-08-18 US US16/303,600 patent/US11059903B2/en active Active
- 2017-08-18 CN CN201780044227.8A patent/CN110049999B/zh active Active
- 2017-08-18 ES ES17757849T patent/ES2983492T3/es active Active
- 2017-08-18 EP EP24173428.4A patent/EP4403226A3/en active Pending
-
2022
- 2022-03-08 JP JP2022035222A patent/JP7486538B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535232A5 (enExample) | ||
| JP2019527561A5 (enExample) | ||
| Tran et al. | 99mTc-maEEE-ZHER2: 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors | |
| RU2673908C2 (ru) | Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения | |
| Adumeau et al. | A pretargeted approach for the multimodal PET/NIRF imaging of colorectal cancer | |
| Hong et al. | Positron emission tomography imaging of prostate cancer | |
| Leyton et al. | Humanized radioiodinated minibody for imaging of prostate stem cell antigen–expressing tumors | |
| Westerlund et al. | Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic affibody molecules | |
| Tolmachev et al. | Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets | |
| TWI795415B (zh) | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 | |
| ES2800602T3 (es) | Procedimientos y composiciones relacionados con los fragmentos de anticuerpos monocatenarios que se unen a la glucoproteína 72 asociada a tumor (TAG-72) | |
| JP2019511201A5 (enExample) | ||
| CA2646329A1 (en) | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting | |
| TWI780082B (zh) | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 | |
| Rinne et al. | PET and SPECT imaging of the EGFR family (RTK class I) in oncology | |
| ES2925224T3 (es) | Anticuerpos monoclonales humanos contra EphA4 y su uso | |
| Maina et al. | From bench to bed: New gastrin-releasing peptide receptor-directed radioligands and their use in prostate cancer | |
| EP4403226A3 (en) | Anti-psma antibodies, uses thereof and conjugates thereof | |
| JP2020504607A5 (enExample) | ||
| Luo et al. | Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer | |
| Ross et al. | Antibody-based therapeutics: focus on prostate cancer | |
| CA3168866A1 (en) | Anti-meflin antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody | |
| Luca et al. | Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives | |
| US8039598B2 (en) | Met fab and SCFV fragments | |
| Altai et al. | Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine |